ESR1 and breast carcinoma: Established markers are hormone receptors (ER, PR), Her2 status, and proliferation index via Ki67 labelling, which must be determined in all newly diagnosed breast cancer and should be retested in recurring or metastatic lesions, if tissue availability is given [12, 43, 44].